NEW YORK (TheStreet) -- CHANGE IN RATINGS
downgraded at Deutsche from Buy to Hold. $18 price target. One-time events are offsetting the company's benefit from higher aluminum prices.
rated new Neutral at Goldman Sachs. $40 price target. Assets are growing and the company can gain market share in the IRA space.
upgraded at UBS from Neutral to Buy. Estimates also upped, given higher expected LED demand. $92 price target.
downgraded at Kaufman from Buy to Hold. $58 price target. Company may fall short of sales growth targets.
target boosted at Barclays to $22. Mortgage insurers should benefit from new mortgage loan modifications. Overweight rating.
downgraded at Deutsche from Buy to Hold. Valuation call, based on a $19 price target. Stock is up 63% since 2010.
Jack in the Box
rated new Equal-weight at Barclays. $23 price target. Stock could be range-bound in the coming quarters.
upgraded at Wells to Outperform. Estimates also boosted, as the company should show strong earnings momentum in its upcoming report.
downgraded at Goldman to Sell. $14 price target. Company has lost market share and pricing for recruitment adds will likely not fully recover.
downgraded at FBR from Outperform to Market Perform. $60 price target. Valuation call, as there is limited near-term upside to expectations.
upgraded at Credit Suisse from Neutral to Outperform. $65 price target. Company has superior and more reliable growth than its peers.
downgraded at Deutsche to Hold. $15 price target. Company will be hurt by recent tragic accident.
upgraded at Goldman from Sell to Neutral. $47 price target. Estimates also upped, as pharma advertising will continue to move online.
STOCK COMMENTS / EPS CHANGES
numbers raised at JP Morgan. Price target raised to $305 from $240. 2010 EPS estimates raised to $12.74 from $11.59.
estimates, target raised at Kaufman. Shares of AAPL now seen reaching $295. Estimates also boosted, because of expected strong iPad sales. Buy rating.
estimates upped at Goldman. BMC estimates were increased through 2012. Company should see margin growth and also benefit from share buybacks. Neutral rating and $43 price target.
target upped at Credit Suisse. Shares of EW now seen reaching $112. Favorable jury award regarding a valve patent will help the company going forward. Outperform rating.
estimates, target raised at Goldman. Shares of GLW now seen reaching $24. Estimates also increased, given a tight supply outlook for LCD glass. Buy rating.
estimates raised at FBR. HIG estimates were increased through 2011. Company is keeping costs down and can generate a higher ROE. Market Perform rating and $29 price target.
estimates, target upped at Goldman. KMX estimates were increased through 2011. Company seeing higher sales and gross margin. Sell rating and new $24 price target.
estimates, target lowered at UBS. MON estimates were cut through 2011. Company will have low pricing for new products. Buy rating and new $89 price target.
estimates, target lowered at Goldman. MOS estimates were reduced through 2012. Company is seeing lower phosphate volumes and margins. Buy rating and new $68 price target.
estimates, target boosted at UBS. Shares of MOS now seen reaching $67. Estimates also raised, as the company is seeing higher volumes. Neutral rating.
estimates cut at UBS through 2011. ARD acquisition should cut into earnings. Buy rating and $10 price target.
estimates, target raised at Goldman. Shares of VALE now seen reaching $47. Estimates also boosted, given the new iron ore pricing structure. Buy rating.
numbers boosted at Credit Suisse. Shares of WCC now seen reaching $40. Estimates also raised, as the company is positioned to benefit from an industrial recovery. Neutral rating.
This article was written by a staff member of TheStreet.com.